

# Rolf W Sparidans

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4113056/publications.pdf>

Version: 2024-02-01

84  
papers

2,029  
citations

236612

25  
h-index

276539

41  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2600  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 319-326.   | 1.9 | 171       |
| 2  | Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. <i>International Journal of Cancer</i> , 2014, 134, 1484-1494.  | 2.3 | 127       |
| 3  | Oral Availability and Brain Penetration of the B-RAF <sup>V600E</sup> Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. <i>Molecular Pharmaceutics</i> , 2012, 9, 3236-3245.   | 2.3 | 113       |
| 4  | Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). <i>Pharmaceutical Research</i> , 2015, 32, 37-46.   | 1.7 | 79        |
| 5  | Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters. <i>Molecular Pharmacology</i> , 2010, 77, 687-694.   | 1.0 | 67        |
| 6  | Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 872, 77-82.  | 1.2 | 63        |
| 7  | Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. <i>Drug Metabolism and Disposition</i> , 2011, 39, 729-735.  | 1.7 | 62        |
| 8  | Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). <i>Pharmacological Research</i> , 2015, 102, 200-207.   | 3.1 | 59        |
| 9  | Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). <i>Pharmaceutical Research</i> , 2015, 32, 2205-2216.   | 1.7 | 53        |
| 10 | Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 5100-5109.  | 3.2 | 49        |
| 11 | Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 486-494.   | 1.3 | 48        |
| 12 | Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 4090-4096.  | 1.2 | 43        |
| 13 | Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. <i>Pharmacological Research</i> , 2017, 120, 43-50.  | 3.1 | 43        |
| 14 | Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 791, 227-233.   | 1.2 | 40        |
| 15 | Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 123-131. | 1.4 | 39        |
| 16 | Liquid chromatography-tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 80-85.  | 1.2 | 38        |
| 17 | In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis <sup>®</sup> , Trabectedin <sup>®</sup> ), a novel marine anti-cancer drug. <i>Investigational New Drugs</i> , 2006, 24, 3-14.   | 1.2 | 36        |
| 18 | P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450 <sup>3A</sup> (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>International Journal of Cancer</i> , 2018, 143, 2029-2038.   | 2.3 | 32        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 269-276.  | 1.2 | 31        |
| 20 | P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. <i>Pharmacological Research</i> , 2018, 129, 414-423.  | 3.1 | 31        |
| 21 | Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O <sup>6</sup> -desmethyl metabolites of erlotinib and gefitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 390-398. | 1.2 | 30        |
| 22 | Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1851-1856.   | 1.2 | 29        |
| 23 | P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. <i>Clinical Cancer Research</i> , 2014, 20, 3133-3145.  | 3.2 | 29        |
| 24 | Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). <i>Pharmacological Research</i> , 2019, 146, 104297.   | 3.1 | 29        |
| 25 | Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 244-263.   | 1.4 | 26        |
| 26 | Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and $\beta$ -ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 839, 45-53.   | 1.2 | 25        |
| 27 | Brain Accumulation of Ponatinib and Its Active Metabolite, <i>N</i> -Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). <i>Molecular Pharmaceutics</i> , 2017, 14, 3258-3268.  | 2.3 | 25        |
| 28 | P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. <i>Pharmacological Research</i> , 2018, 137, 47-55.   | 3.1 | 25        |
| 29 | Organic Anion-Transporting Polypeptides 1a/1b Control the Hepatic Uptake of Pravastatin in Mice. <i>Molecular Pharmaceutics</i> , 2012, 9, 2497-2504.   | 2.3 | 24        |
| 30 | Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 905, 150-154.   | 1.2 | 23        |
| 31 | Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. <i>International Journal of Nanomedicine</i> , 2012, 7, 417.  | 3.3 | 22        |
| 32 | Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. <i>Biomedical Chromatography</i> , 2014, 28, 1366-1370.  | 0.8 | 22        |
| 33 | Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. <i>Pharmaceutical Research</i> , 2018, 35, 85.  | 1.7 | 22        |
| 34 | Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 136-143.  | 1.4 | 22        |
| 35 | Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1012-1013, 118-123.  | 1.2 | 18        |
| 36 | Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 780, 423-430.  | 1.2 | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Liquid chromatographic assay for the protease inhibitor atazanavir in plasma. <i>Biomedical Chromatography</i> , 2006, 20, 72-76.  | 0.8 | 17        |
| 38 | Dendrimer-Based Macromolecular Conjugate for the Kidney-Directed Delivery of a Multitargeted Sunitinib Analogue. <i>Macromolecular Bioscience</i> , 2012, 12, 93-103.  | 2.1 | 17        |
| 39 | Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 120-130.   | 2.0 | 17        |
| 40 | Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 204-208.                      | 1.2 | 16        |
| 41 | Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 905, 137-140.                      | 1.2 | 15        |
| 42 | <i>P</i> -Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. <i>Molecular Pharmaceutics</i> , 2018, 15, 5124-5134.   | 2.3 | 15        |
| 43 | Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma. <i>Biomedical Chromatography</i> , 2007, 21, 621-627.  | 0.8 | 14        |
| 44 | Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 889-890, 144-147.  | 1.2 | 14        |
| 45 | Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 626-629.  | 1.4 | 14        |
| 46 | OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. <i>British Journal of Pharmacology</i> , 2020, 177, 3060-3074.   | 2.7 | 14        |
| 47 | Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 855, 200-210. | 1.2 | 13        |
| 48 | The potency of clobetasol propionate: Serum levels of clobetasol propionate and adrenal function during therapy with 0.05% clobetasol propionate in patients with severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2012, 23, 16-20.                                    | 1.1 | 13        |
| 49 | Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 925, 124-128.   | 1.2 | 12        |
| 50 | Quantification of cystine in human renal proximal tubule cells using liquid chromatography-tandem mass spectrometry. <i>Biomedical Chromatography</i> , 2018, 32, e4238.   | 0.8 | 12        |
| 51 | Extrahepatic metabolism of ibrutinib. <i>Investigational New Drugs</i> , 2021, 39, 1-14.   | 1.2 | 12        |
| 52 | Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue. <i>Biomedical Chromatography</i> , 2003, 17, 458-464.  | 0.8 | 11        |
| 53 | Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2751-2759.                           | 1.2 | 11        |
| 54 | Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1023-1024, 24-29.   | 1.2 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1174, 122718.   | 1.2 | 11        |
| 56 | Liquid chromatography-tandem mass spectrometry assay for the EGFR inhibitor pelitinib in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 934, 22-25.  | 1.2 | 10        |
| 57 | Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 216-220.   | 1.4 | 10        |
| 58 | Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1102-1103, 167-172.         | 1.2 | 10        |
| 59 | P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. <i>International Journal of Pharmaceutics</i> , 2019, 556, 172-180.   | 2.6 | 10        |
| 60 | P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). <i>International Journal of Pharmaceutics</i> , 2020, 573, 118842.   | 2.6 | 10        |
| 61 | Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 895-896, 174-177.  | 1.2 | 9         |
| 62 | Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1110-1111, 116-123.  | 1.2 | 9         |
| 63 | Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1147, 122131.            | 1.2 | 8         |
| 64 | Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4- $\epsilon^2$ -hydrazino-2-stilbazole. <i>Biomedical Chromatography</i> , 2004, 18, 16-20.   | 0.8 | 7         |
| 65 | Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 300-305. | 1.2 | 7         |
| 66 | Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1144, 122098.                             | 1.2 | 7         |
| 67 | Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2150-2154.  | 1.2 | 6         |
| 68 | ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1173-1182.  | 1.9 | 6         |
| 69 | ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. <i>Pharmacological Research</i> , 2021, 172, 105850.   | 3.1 | 6         |
| 70 | Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1162, 122466.   | 1.2 | 6         |
| 71 | ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. <i>Pharmaceutics</i> , 2021, 13, 1761.  | 2.0 | 6         |
| 72 | Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1122-1123, 78-82.  | 1.2 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | A robust, accurate, sensitive LC-MS/MS method to measure indoxyl sulfate, validated for plasma and kidney cells. <i>Biomedical Chromatography</i> , 2022, 36, .  | 0.8 | 5         |
| 74 | Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 403-408.  | 1.4 | 4         |
| 75 | Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1166, 122554. | 1.2 | 4         |
| 76 | ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. <i>Pharmacological Research</i> , 2022, 178, 106137.   | 3.1 | 4         |
| 77 | Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N+glucuronide in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 895-896, 169-173.                                    | 1.2 | 2         |
| 78 | Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 144-148.   | 1.4 | 2         |
| 79 | P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). <i>Pharmaceuticals</i> , 2021, 14, 1087.  | 1.7 | 2         |
| 80 | Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma. <i>Biomedical Chromatography</i> , 2006, 20, 671-673.   | 0.8 | 1         |
| 81 | Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2168-2172.   | 1.2 | 1         |
| 82 | Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 207, 114421.  | 1.4 | 1         |
| 83 | MO622IMPAIRED PROTEIN-BOUND UREMIC TOXIN EXCRETION SUGGESTS TUBULAR DYSFUNCTION IN DIABETIC NEPHROPATHY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .  | 0.4 | 0         |
| 84 | Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 170, 197-207.  | 2.0 | 0         |